TBD: Brenda Gallie
to
![](/sites/default/files/media/image/2024-07/brenda.jpeg)
Brenda Gallie MD, FRCSC, CM, OOnt
Professor, Departments Ophthalmology, Medical Biophysics, and Molecular Genetics
University of Toronto
Brenda Gallie is Professor in Medical Biophysics, Molecular Genetics, and Ophthalmology. She directs the Retinoblastoma Program at the Hospital for Sick Children. She received The Order of Ontario and Membership, Order of Canada for delivering personalized medicine and predictive genomic studies to families. To address the global disparity of cancer care and outcomes, she developed point-of-care cancer site-specific databases, now supporting global collaboration and treatment guidelines.
The Gallie lab since 1974 has focused on all aspects of the rare children' s eye cancer, retinoblastoma, including molecular pathogenesis and clinical impact. We identified that somatic inactivation of the RB1 gene initiated retinoblastoma tumors, pointing to the role of tumor suppressor genes in cancer. If the first mutant RB1 allele (M1) arises in the germline, it predisposes to bilateral retinoblastoma and multiple other cancers, when the second allele (M2) undergoes somatic inactivation in embryonic retina and other tissues. We went on to characterize key M3 genetic changes in retinoblastoma progression and the genes involved (KIF14, CDH11, E2F3/DEK, and MYCN).
This page was last updated on Wednesday, July 10, 2024